Higher radiation dose to the immune cells correlates with worse tumor control and overall survival in patients with stage iii nsclc: A secondary analysis of rtog0617

Jian Yue Jin, Chen Hu, Ying Xiao, Hong Zhang, Rebecca Paulus, Susannah G. Ellsworth, Steven E. Schild, Jeffrey A. Bogart, Michael Chris Dobelbower, Vivek S. Kavadi, Samir Narayan, Puneeth Iyengar, Cliff Robinson, Joel S. Greenberger, Christopher Koprowski, Mitchell Machtay, Walter Curran, Hak Choy, Jeffrey D. Bradley, Feng Ming Kong

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: We hypothesized that the Effective radiation Dose to the Immune Cells (EDIC) in circulating blood is a significant factor for the treatment outcome in patients with locally advanced non-small-cell lung cancer (NSCLC). Methods: This is a secondary study of a phase III trial, NRG/RTOG 0617, in patients with stage III NSCLC treated with radiation-based treatment. The EDIC was computed as equivalent uniform dose to the entire blood based on radiation doses to all blood-containing organs, with consideration of blood flow and fractionation effect. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS) and local progression-free survival (LPFS). The EDIC–survival relationship was analyzed with consideration of clinical significant factors. Results: A total of 456 patients were eligible. The median EDIC values were 5.6 Gy (range, 2.1–12.2 Gy) and 6.3 Gy (2.1–11.6 Gy) for the low-and high-dose groups, respectively. The EDIC was significantly associated with OS (hazard ratio [HR] = 1.12, p = 0.005) and LPFS (HR = 1.09, p = 0.02) but PFS (HR = 1.05, p = 0.17) after adjustment for tumor dose, gross tumor volume and other factors. OS decreased with an increasing EDIC in a non-linear pattern: the two-year OS decreased first with a slope of 8%/Gy when the EDIC < 6 Gy, remained relatively unchanged when the EDIC was 6–8 Gy, and followed by a further reduction with a slope of 12%/Gy when the EDIC > 8 Gy. Conclusions: The EDIC is a significant independent risk factor for poor OS and LPFS in RTOG 0617 patients with stage III NSCLC, suggesting that radiation dose to circulating immune cells is critical for tumor control. Organ at risk for the immune system should be considered during RT plan.

Original languageEnglish (US)
Article number6193
JournalCancers
Volume13
Issue number24
DOIs
StatePublished - Dec 1 2021

Keywords

  • Non-small-cell lung cancer
  • Radiation-induced immune toxicity
  • Radiotherapy
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Higher radiation dose to the immune cells correlates with worse tumor control and overall survival in patients with stage iii nsclc: A secondary analysis of rtog0617'. Together they form a unique fingerprint.

Cite this